OPKO Health (OPK) Stock Overview
A healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OPK Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
OPKO Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.55 |
| 52 Week High | US$2.04 |
| 52 Week Low | US$1.11 |
| Beta | 1.5 |
| 1 Month Change | 9.15% |
| 3 Month Change | 13.97% |
| 1 Year Change | 3.33% |
| 3 Year Change | -10.92% |
| 5 Year Change | -61.92% |
| Change since IPO | -65.56% |
Recent News & Updates
Recent updates
OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Not Quite Adding Up
Sep 19
OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy
Jun 11What OPKO Health, Inc.'s (NASDAQ:OPK) P/S Is Not Telling You
May 24OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
May 01
Phase 1 Trials With Merck And Pfizer Will Unlock New Opportunities
Progress in ModeX's pipeline and the Merck collaboration could drive growth in the Pharmaceuticals segment with potential revenue impacts from trials and commercialization.The OPKO Health, Inc. (NASDAQ:OPK) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 05OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Could Signal Some Risk
Jan 14OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 09Not Enough To Keep OPKO Health Flying
Aug 28OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar
Dec 30Is OPKO Health (NASDAQ:OPK) A Risky Investment?
Oct 03OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up
Jul 24Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?
Jun 07Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?
Jan 04OPKO Health: Assessing If Significant Potential Can Be Realized
Sep 15OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Sep 05Shareholder Returns
| OPK | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 0.8% |
| 1Y | 3.3% | -18.4% | 17.8% |
Return vs Industry: OPK exceeded the US Healthcare industry which returned -18.1% over the past year.
Return vs Market: OPK underperformed the US Market which returned 17.8% over the past year.
Price Volatility
| OPK volatility | |
|---|---|
| OPK Average Weekly Movement | 5.9% |
| Healthcare Industry Average Movement | 6.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OPK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OPK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,997 | Phil Frost | www.opko.com |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.
OPKO Health, Inc. Fundamentals Summary
| OPK fundamental statistics | |
|---|---|
| Market cap | US$1.22b |
| Earnings (TTM) | -US$177.14m |
| Revenue (TTM) | US$664.03m |
Is OPK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPK income statement (TTM) | |
|---|---|
| Revenue | US$664.03m |
| Cost of Revenue | US$567.60m |
| Gross Profit | US$96.43m |
| Other Expenses | US$273.57m |
| Earnings | -US$177.14m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 14.52% |
| Net Profit Margin | -26.68% |
| Debt/Equity Ratio | 26.5% |
How did OPK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/08 11:06 |
| End of Day Share Price | 2025/10/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OPKO Health, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Louise Chen | Cantor Fitzgerald & Co. |
| Dana Flanders | Guggenheim Securities, LLC |